Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029296 · ClinicalTrials.gov registry record · Early Phase 1
Diclofenac as a KMO Inhibitor
A Early Phase 1 study of Alcohol Use Disorder, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06029296: Active Early Phase 1 study of Alcohol Use Disorder, sponsored by University of Maryland, Baltimore.
NCT06029296 is a Early Phase 1 study of Alcohol Use Disorder that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 12 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06029296, a Early Phase 1 study of Alcohol Use Disorder, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.
Primary Outcome
Serum levels of Kynurenic Acid
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Diclofenac
Study Locations (1)
Maryland
- Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP) - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2026-01 |
| Phase | Early Phase 1 |
What the registry record for NCT06029296 still lists
NCT06029296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06029296 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06029296 about?
NCT06029296 is a clinical study titled "Diclofenac as a KMO Inhibitor". This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The...
What is the current status of trial NCT06029296?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2024-07-31. Estimated completion is 2026-01.
What conditions does trial NCT06029296 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT06029296?
The interventions under investigation include: Placebo (DRUG), Diclofenac (DRUG).
Who is sponsoring clinical trial NCT06029296?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06029296 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06029296's enrollment target sits among peer trials
12 177th of 184 higher than 7 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impulsivity Domains and Subjective Response
RECRUITING · Early Phase 1
-
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
RECRUITING · Early Phase 1
-
Suvorexant and Alcohol
RECRUITING · Early Phase 1
-
Anxiety During Abstinence in AUD
RECRUITING · Early Phase 1
-
Behavioral Alcohol Responses (BAR) Study
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI